GLPG 2851

Drug Profile

GLPG 2851

Alternative Names: GLPG2851

Latest Information Update: 31 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galapagos NV
  • Developer AbbVie; Galapagos NV
  • Class Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cystic fibrosis

Most Recent Events

  • 31 Jul 2017 Galapagos plans a phase I trial for Cystic fibrosis in 2017
  • 24 Jul 2017 Preclinical trials in Cystic fibrosis in Belgium (unspecified route) (Galapagos pipeline, July 2017)
  • 23 Mar 2017 Galapagos has patents pending for GLPG 2851 in USA and Taiwan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top